Search API
SK bioscience today announced the company has received the WHO Emergency Use Listing (EUL) of its COVID-19 vaccine, SKYCovione™ (SKYCovion™, GBP510).
This COVID-19 vaccine was developed with the Institute for Protein Design (IPD) at the University of Washington SCHOOL OF MEDICINE and uses GSK's pandemic adjuvant.
SKYCovione is also the world's first medicine developed using computational protein design, an approach that uses Rosetta software to engineer protein structures with enough precision to place individual atoms exactly where desired.
Jaeyong Ahn, CEO of SK bioscience, commented in a press release on June 19, 2023, "Based on the immunogenicity and safety profile, SKYCovione has become the first Korean vaccine to be granted to the WHO EUL."
"We will be committed to developing more vaccines not just to strengthen Korea's vaccine sovereignty but also to enable equitable access to the vaccine."
The development of SKYCovione has been supported by funding from the Bill & Melinda Gates Foundation and Coalition for Epidemic Preparedness Innovations with support from the European Horizon 2020 Programme.
SKYCovione (known as SKYCovion in the UK) was approved by the Medicines and Healthcare products Regulatory Agency for adults in May 2023.
SKYCovione is a self-assembled nanoparticle vaccine targeting the receptor binding domain of the SARS-CoV-2 Spike protein for SARS-CoV-2.
The vaccine can be stored between 2-8 °C, making it suitable for use in countries where ultra-low cold chain storage facilities are unavailable. The ease of distribution helps to achieve greater access to vaccines in low-income countries.
Other COVID-19 vaccine news is posted by Precision Vaccinations.
International visitors may be exposed to several infectious diseases in the Republic of Costa Rica in 2023, reported the U.S. Centers for Disease Control and Prevention (CDC).
As of June 18, 2023, though malaria cases have been reported primarily in the Caribbean province of Limon, there is a risk of contracting this mosquito-transmitted disease anywhere in Costa Rica, says the local U.S. embassy.
Costa Rica has been advancing various programs toward the elimination of malaria by the year 2025.
Additionally, Costa Rica has been suffering an outbreak of dengue (both classic and hemorrhagic) for a few years.
As of epidemiological week #16 in 2023, a total of 1,179 cases of dengue were reported, with most of the dengue cases found in the Huetar Caribe and Central Sur regions.
Dengue is a vaccine-preventable disease, with two vaccines currently authorized in various countries.
And from a security perspective, the U.S. Embassy in San Jose recently alerted U.S. citizens of increasing civil unrest in San Jose and suggests enrolling in the Smart Traveler Program to receive emergency notifications.
The U.S. Centers for Disease Control and Prevention (CDC) Weekly U.S. Influenza Surveillance Report indicated minimal flu activity in the U.S.
Based on the National Center for Health Statistics Mortality Surveillance data available on June 15, 2023, 6.3% of the deaths during week #23 were due to pneumonia, influenza, and/or COVID-19 (PIC).
Among the 1,295 PIC deaths reported for last week, ten listed influenza.
Furthermore, in the southern hemisphere, Australia's Department of Health and Aged Care published report No. 4, which stated there is not enough information to assess the potential severity of the 2023 influenza season.
Since seasonal surveillance commenced in Australia in April 2023, there have been only 518 sentinel hospital admissions with confirmed influenza as of June 2, 2023.
As of June 18, 2023, various flu shots are available worldwide.
The World Health Organization (WHO) recently reported nearly 1.5 million new COVID-19 cases and 7,300 related fatalities in the last 28 days (May 15 to June 11, 2023).
As of June 15, 2023, all six WHO regions reported (Edition #147) decreases in COVID-19 cases and fatalities.
During the current 28-day period, only 59% of countries and territories reported cases, a proportion that has been declining since mid-2022.
Various COVID-19 vaccines and antibody therapies remain available in most countries as of June 18, 2023.
The World Health Organization (WHO) recently published Influenza Update N° 447, which presented data on the current respiratory syncytial virus (RSV) seasonality.
In the U.S., the 2022–23 RSV season it started later than during 2021–2022 but earlier than the prepandemic seasons, suggesting a return toward prepandemic seasonality.
Across both prepandemic and pandemic years, RSV circulation in the U.S. began in Florida.
Globally, RSV activity was generally low except in Australia, and a few countries in the Region of the Americas reported the WHO on June 12, 2023.
RSV activity decreased to low levels in Central America and the Caribbeans while increasing in a few countries in tropical and temperate South America.
In South Africa, the RSV detection rate among children under five years of age in pneumonia surveillance remained at a low level.
As of June 17, 2023, RSV vaccines for adults and antibody therapy for infants are authorized in various countries.
The Colorado Department of Public Health and Environment and Denver Department of Public Health & Environment (DDPHE) announced on June 12, 2023, new mpox patients and outbreaks are possible, as demonstrated by three recent mpox cases.
Unfortunately, two of the three Colorado patients involve people fully vaccinated with two doses of the JYNNEOS® (MVA-BN) vaccine.
“While (mpox) cases remain low in Colorado and nationally compared to last year’s outbreak, now is a great time to get vaccinated if recommended for you,” said Dr. Rachel Herlihy, Colorado state epidemiologist, in a press release.
“Vaccination provides the best protection against illness and hospitalizations, and we want Coloradans to know about available testing and treatment options if they get mpox.”
CDPHE confirmed it would resume updating mpox case counts weekly but will not release any additional demographic information about individual cases at this time to protect patient privacy.
Other sexually transmitted disease news is posted by Precision Vaccinations.
UK Health Security Agency (UKHSA) announced today London had reported 11 new mpox cases within the past few weeks.
Most of these cases were in unvaccinated individuals. However, three were in those who had only received one dose of Bavarian Nordic's JYNNEOS® (MVA-BN) vaccine.
In response to London's mpox outbreak, the UKHSA vaccinations would be offer in London to qualifying men beyond July 2023.
After the end of July, people who regularly travel to London or abroad to have sex and are eligible for the JYNNEOS vaccine are empowered to schedule a London-based appointment using the vaccine finder.
Dr. Claire Dewsnap, President of the British Association for Sexual Health and HIV, commented in a related press release, "We strongly encourage all those eligible to book an appointment to receive a mpox vaccination, especially given the worrying recent spike in cases."
"One dose of the vaccine protects against the virus, and the second dose can further prevent severe symptoms and transmission."
"This is particularly important as we move into the summer months, during which festivals and events are more common, increasing the likelihood for people to have multiple sexual partners."
As of June 16, 2023, 21 mpox cases have been reported in the UK.
Other mpox outbreaks are posted by Vax-Before-Travel.
